HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.
![handle is hein.congrecreports/crptxadrh0001 and id is 1 raw text is: AUTHENTICATED
U.S. GOVERNMENT
INFORMATION
GP
116TH CONGRESS [REPT. 116-688
2d Session HOUSE OF REPRESENTATIVES Part 1
PRESCRIPTION DRUG SUNSHINE, TRANSPARENCY,
ACCOUNTABILITY AND REPORTING ACT
DECEMBER 24, 2020.-Committed to the Committee of the Whole House on the State
of the Union and ordered to be printed
Mr. NEAL, from the Committee on Ways and Means,
submitted the following
R E P O R T
[To accompany H.R. 2113]
[Including cost estimate of the Congressional Budget Office]
The Committee on Ways and Means, to whom was referred the
bill (H.R. 2113) to amend titles XI and XVIII of the Social Security
Act to provide for drug manufacturer price transparency, to require
certain manufacturers to report on product samples provided to
certain health care providers, and for other purposes, having con-
sidered the same, reports favorably thereon with an amendment
and recommends that the bill as amended do pass.
CONTENTS
Page
I. SUMMARY AND BACKGROUND ................................................................. 8
A. Purpose and Summary ......................................................................... 8
B. Background and Need for Legislation ................................................ 8
C. Legislative History ............................................................................... 9
II. EXPLANATION OF THE BILL ...................................................................... 10
A. Section 2-Drug Manufacturer Price Transparency .......................... 10
B. Section 3-Requirement for manufacturers of certain drugs, de-
vices, biologicals, and medical supplies to report on product sam-
ples provided to certain health care providers ................................ 15
C. Section 4-Analysis and report on inpatient hospital drug costs ..... 18
D. Section 5-Public disclosure of drug discounts .................................. 19
E. Section 6-Requiring certain manufacturers to report drug pricing
information with respect to drugs under the Medicare program ... 21
III. VOTES OF THE COMMITTEE ...................................................................... 22
IV. BUDGET EFFECTS OF THE BILL .............................................................. 23
A. Committee Estimate of Budgetary Effects ......................................... 23
B. Statement Regarding New Budget Authority and Tax Expendi-
tures Budget Authority ...................................................................... 23
C. Cost Estimate Prepared by the Congressional Budget Office ........... 23
19-006](ViewImageLocal?handle=hein.congrecreports/crptxadrh0001&div=1&collection=&method=preview&ext=.png&size=3)